Department of Mechanical and Aerospace Engineering.
Department of Biomedical Engineering.
Curr Opin Hematol. 2022 Nov 1;29(6):327-334. doi: 10.1097/MOH.0000000000000731. Epub 2022 Jul 18.
This review briefly summarizes the significant impact of thromboinflammation in sickle cell disease in relation to recent advances in biomarkers that are used in functional microfluidic assays.
Sickle cell disease (SCD) is an inherited hemoglobinopathy that affects 100 000 Americans and millions worldwide. Patients with SCD exhibit chronic haemolysis, chronic inflammation and thrombosis, and vaso-occlusion, triggering various clinical complications, including organ damage and increased mortality and morbidity. Recent advances in functional microfluidic assays provide direct biomarkers of disease, including abnormal white blood cell and red blood cell adhesion, cell aggregation, endothelial degradation and contraction, and thrombus formation.
Novel and emerging functional microfluidic assays are a promising and feasible strategy to comprehensively characterize thromboinflammatory reactions in SCD, which can be used for personalized risk assessment and tailored therapeutic decisions.
本文简要总结了血栓炎症在镰状细胞病中的重要作用，以及近年来在用于功能性微流控分析的生物标志物方面的进展。
镰状细胞病（SCD）是一种遗传性血红蛋白病，影响着 10 万美国人和全球数百万人。SCD 患者表现出慢性溶血、慢性炎症和血栓形成以及血管阻塞，引发各种临床并发症，包括器官损伤以及死亡率和发病率的增加。功能性微流控分析的最新进展提供了疾病的直接生物标志物，包括异常的白细胞和红细胞黏附、细胞聚集、内皮降解和收缩以及血栓形成。
新型和新兴的功能性微流控分析是全面描述 SCD 中血栓炎症反应的有前途且可行的策略，可用于个性化风险评估和针对性治疗决策。
